| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AMGN | Common Stock | Options Exercise | $1.36M | +8.71K | +12.18% | $156.35 | 80.3K | Feb 19, 2025 | Direct | F1 |
| transaction | AMGN | Common Stock | Sale | -$2.55M | -8.71K | -10.85% | $292.84 | 71.5K | Feb 19, 2025 | Direct | F2, F3 |
| holding | AMGN | Common Stock | 869 | Feb 19, 2025 | 401K Plan | F4 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AMGN | Nqso (Right to Buy) | Options Exercise | $0 | -8.71K | -100% | $0.00 | 0 | Feb 19, 2025 | Common Stock | 8.71K | $156.35 | Direct |
| Id | Content |
|---|---|
| F1 | These shares were acquired in connection with the exercise of stock options expiring on May 3, 2026. |
| F2 | The price reported is an average price. The prices ranged from $292.7523 to $293.00 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer. |
| F3 | These shares include 667 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
| F4 | These shares are acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing. |